{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T13:28:08Z","timestamp":1707312488777},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10822-022-00457-2","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T12:03:47Z","timestamp":1658405027000},"page":"329-338","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is the reductionist paradox an Achilles Heel of drug discovery?"],"prefix":"10.1007","volume":"36","author":[{"given":"Gerry","family":"Maggiora","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"457_CR1","unstructured":"BrainyQuotes.com. Accessed 30 Aug 2021"},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10822-011-9447-8","volume":"25","author":"GM Maggiora","year":"2011","unstructured":"Maggiora GM (2011) The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs? J Comput Aided Mol Des 25:699\u2013708","journal-title":"J Comput Aided Mol Des"},{"key":"457_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nchembio.1813","volume":"11","author":"ME Bunnage","year":"2015","unstructured":"Bunnage ME, Gilbert AM, Jones LH, Hett EC (2015) Know your target, know your molecule. Nat Chem Biol 11:368\u2013372","journal-title":"Nat Chem Biol"},{"key":"457_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.drudis.2006.03.015","volume":"11","author":"F Sams-Dodd","year":"2006","unstructured":"Sams-Dodd F (2006) Drug discovery: selecting the optimal approach. Drug Disc Today 11:465\u2013472","journal-title":"Drug Disc Today"},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0958-1669(99)00051-8","volume":"11","author":"SA Sundberg","year":"2000","unstructured":"Sundberg SA (2000) High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol 11:47\u201353","journal-title":"Curr Opin Biotechnol"},{"key":"457_CR6","doi-asserted-by":"publisher","unstructured":"Bokhari FF, Albukhari A (2021) Design and implementation of high throughput screening assays for drug discoveries. https:\/\/doi.org\/10.5772\/intechopen.98733","DOI":"10.5772\/intechopen.98733"},{"key":"457_CR7","doi-asserted-by":"crossref","unstructured":"Berry M, Fielding B, Gamiedien J (2015) Practical considerations in virtual screening and molecular docking. In: Arabnia H, Tran QN (eds) Emerging trends in computational biology, bioinformatics, and system biology, Chapter 27, 1st edn. Morgan Kaufman, Burlington","DOI":"10.1016\/B978-0-12-802508-6.00027-2"},{"key":"457_CR8","doi-asserted-by":"publisher","unstructured":"Prieto-Martinez FD, Arciniega M, Medina-Franco JL (2018) Molecular docking: current advances and challenges. TIP Revista Especializada en Cienias Qu\u00edmico-Biol\u00f3gicas 21. https:\/\/doi.org\/10.22201\/fesz.23958723e.2018.0.143","DOI":"10.22201\/fesz.23958723e.2018.0.143"},{"key":"457_CR9","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.3390\/ijms20184574","volume":"20","author":"PHM Torres","year":"2019","unstructured":"Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP (2019) Key topics in molecular docking for drug design. Int J Mol Sci 20:4574. https:\/\/doi.org\/10.3390\/ijms20184574","journal-title":"Int J Mol Sci"},{"key":"457_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","volume":"566","author":"J Lyu","year":"2019","unstructured":"Lyu J, Wang S, Balius TE (2019) Ultra-large library docking for discovering new chemotypes. Nature 566:224\u2013229","journal-title":"Nature"},{"key":"457_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000028","author":"A-T Ton","year":"2020","unstructured":"Ton A-T, Gentile F, Hsing M, Ban F, Cherkasov A (2020) Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 13 billion compounds. Mol Inf. https:\/\/doi.org\/10.1002\/minf.202000028","journal-title":"Mol Inf"},{"key":"457_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/acs.jcim.6b00491","volume":"57","author":"W Zhang","year":"2017","unstructured":"Zhang W, Pei J, Lai L (2017) Computational multitarget drug design. J Chem Inf Model 57:403\u2013412","journal-title":"J Chem Inf Model"},{"key":"457_CR13","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","volume":"62","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jiang X, He S, Jiang H, Feng F (2019) Rational design of multitarget-directed ligands: strategies and emerging paradigms. J Med Chem 62:8881\u20138914","journal-title":"J Med Chem"},{"key":"457_CR14","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"A Anighoro","year":"2014","unstructured":"Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacolgy: challenges and opportunities in drug discovery. J Med Chem 57:7874\u20137887","journal-title":"J Med Chem"},{"key":"457_CR15","doi-asserted-by":"crossref","unstructured":"Maggiora GM, Gokhale V (2016) Non-specificity of drug-target interactions\u2014consequences for drug discovery. In: Bienstock RJ, Shanmugasundarm V, Bajorath J (eds) Frontiers in molecular design and chemical information science\u2014Herman Skolnik Award Symposium 2015: J\u00fcrgen Bajorath. American Chemical Society, Washington, DC, pp 91\u2013142","DOI":"10.1021\/bk-2016-1222.ch007"},{"key":"457_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"11","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 11:682\u2013690","journal-title":"Nat Chem Biol"},{"key":"457_CR17","volume-title":"Network medicine\u2014complex systems in human disease and therapeutics","year":"2017","unstructured":"Localzo J, Barab\u00e1si A-L, Silverman EK (eds) (2017) Network medicine\u2014complex systems in human disease and therapeutics. Harvard University Press, Cambridge"},{"key":"457_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/10794","volume":"17","author":"JE Bailey","year":"1999","unstructured":"Bailey JE (1999) Lessons from metabolic engineering for functional genomics and drug discovery. Nat Biotechnol 17:617\u2013618","journal-title":"Nat Biotechnol"},{"issue":"1","key":"457_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","volume":"7","author":"RR Ramsay","year":"2018","unstructured":"Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7(1):3. https:\/\/doi.org\/10.1186\/s40169-017-0181-2","journal-title":"Clin Transl Med"},{"key":"457_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41587-020-0502-7","volume":"38","author":"M Duran-Frigola","year":"2020","unstructured":"Duran-Frigola M, Pauls E, Guitart-Pla O, Bertoni M, Alcalde V, Amat D, Juan-Blanco T, Aloy P (2020) Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker. Nat Biotechnol 38:1087\u20131096","journal-title":"Nat Biotechnol"},{"key":"457_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.chembiol.2017.03.016","volume":"24","author":"FM Drawnel","year":"2017","unstructured":"Drawnel FM, Zhang JD et al (2017) Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery. Cell Chem Biol 24:624\u2013634","journal-title":"Cell Chem Biol"},{"key":"457_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12864-015-1532-2","volume":"16","author":"JD Zhang","year":"2015","unstructured":"Zhang JD, K\u00fcng E, Boess F, Ulrich C, Ebeling M (2015) Pathway reporter genes define molecular phenotypes of human cells. BMC Genom 16:342. https:\/\/doi.org\/10.1186\/s12864-015-1532-2","journal-title":"BMC Genom"},{"key":"457_CR23","unstructured":"The Human Physiome Project (\u2018physi\u2019 means \u2018life\u2019 and \u2018ome\u2019 means \u2018as a whole\u2019): http:\/\/physiomeproject.org\/about\/molecules-to-humankind. Accessed 1 Sept 2021"},{"key":"457_CR24","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1038\/d41586-018-05267-x","volume":"557","author":"N Fleming","year":"2018","unstructured":"Fleming N (2018) How artificial intelligence is changing drug discovery. Nature 557:S55\u2013S57","journal-title":"Nature"},{"key":"457_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drudis.2020.12.009","volume":"26","author":"A Bender","year":"2021","unstructured":"Bender A, Cort\u00e9s-Ciriano I (2021) Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. Drug Disc Today 26:511\u2013524","journal-title":"Drug Disc Today"},{"key":"457_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab430","author":"J Deng","year":"2021","unstructured":"Deng J, Yang Z, Ojima I, Samaras D, Wang F (2021) Artificial intelligence in drug discovery: applications and techniques. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab430","journal-title":"Brief Bioinform"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-022-00457-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-022-00457-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-022-00457-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T08:09:41Z","timestamp":1658822981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-022-00457-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s10822-022-00457-2","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}